|Table of Contents|

Exploring homologous recombination deficiency(HRD) in breast cancer based on genomic scar score(GSS)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 05
Page:
855-860
Research Field:
Publishing date:

Info

Title:
Exploring homologous recombination deficiency(HRD) in breast cancer based on genomic scar score(GSS)
Author(s):
FENG Cong1; LI Jia1; ZHANG Yinbin1; WU Fei1; LIU Mengjie1; CHEN Xi1; LI Chaofan1; WANG Weiwei1; TAN Qinghua2; ZHANG Shuqun1
1.Department of Oncology;2.Department of Orthopedic Surgery,the Second Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710021,China.
Keywords:
breast cancer; BRCA1/2; homologous recombination deficiency; PARP inhibitors; genomic scar score; clinical characteristics
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.05.013
Abstract:
Objective:To reveal the land scape of HRD status in Chinese breast cancer population by using genomic scar score(GSS) and statistically analyze the HRD status and clinical characteristics of breast cancer.Methods:Using AmoyDx HRD Panel to detect 79 breast cancer patients diagnosed in our hospital.Genomic Scar Score(GSS) is determined according to the length of copy number(LCN),the site of copy number(SCN) and the type of copy number(TCN).HRD-positive was defined by BRCA positive and/or GSS score≥50.The relationship between HRD score and clinical characteristics were statistically analyzed by the Chi-square test,Fisher's exact test and Wilcoxon rank sum test.Results:Of the 79 patients,approximately 10.1% were BRCA mutation positive.Approximately 35.4% of the patients were HRD positive.Among TNBC patients,the HRD positive rate was 80% and the BRCA mutation positivity rate was 26.7%.53.4% of TNBC patients were negative for BRCA mutation but positive for HRD.HRD-positive tumors were significantly associated with clinical Ki-67 high(P<0.05),ER negative(P<0.05),and PR negative(P<0.05).The incidence of HRD-positive was also significantly higher in TNBC(80%) than in the Luminal A(7.7%,P<0.05) and Luminal B(27.7%,P<0.05).Conclusion:GSS is an important tool for detecting homologous recombination deficiency in breast cancer and can help identify breast cancer populations with a negative BRCA mutation but positive for HRD.HRD is associated with ER,PR and Ki-67 status in breast cancer.

References:

[1]ODAHARA M,KOBAYASHI Y,SHIKANAI T,et al.Dynamic interplay between nucleoid segregation and genome integrity in chlamydomonas chloroplasts ［J］.Plant Physiol,2016,172(4):2337-2346.
[2]NGUYEN L,J WMM,VAN HOECK A,et al.Pan-cancer landscape of homologous recombination deficiency ［J］.Nat Commun,2020,11(1):5584.
[3]LAFARGUE CJ,DAL MOLIN GZ,SOOD AK,et al.Exploring and comparing adverse events between PARP inhibitors ［J］.Lancet Oncology,2019,20(1):E15-E28.
[4]EXMAN P,BARROSO-SOUSA R,TOLANEY SM.Evidence to date:talazoparib in the treatment of breast cancer ［J］.Onco Targets Ther,2019,12:5177-5187.
[5]ZHANG D,BALDWIN P,LEAL AS,et al.A nano-liposome formulation of the PARP inhibitor talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice ［J］.Theranostics,2019,9(21):6224-6238.
[6]TELLI ML,TIMMS KM,REID J,et al.Homologous recombination deficiency(HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer ［J］.Clin Cancer Res,2016,22(15):3764-3473.
[7]GOU R,DONG H,LIN B.Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy ［J］.Life Sci,2020,261:11841134.
[8]TIMMS KM,ABKEVICH V,HUGHES E,et al.Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes ［J］.Breast Cancer Res,2014,16(6):475.
[9]SZTUPINSZKI Z,DIOSSY M,KRZYSTANEK M,et al.Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer ［J］.NPJ Breast Cancer,2018,4:16.
[10]陈锐,纪元,申鹏,等.同源重组修复缺陷临床检测与应用专家共识(2021版) ［J］.中国癌症防治杂志,2021,13(04):329-338. CHEN R,JI Y,SHEN P,et al.Expert consensus on clinical detection and application of homologous recombination repair deficiency(2021)［J］.Chinese Journal Oncology Prevention and Treatment,2021,13(04):329-338.
[11]SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2022 ［J］.CA Cancer J Clin,2022,72(1):7-33.
[12]GONZALEZ-MARTIN A,POTHURI B,VERGOTE I,et al.Niraparib in patients with newly diagnosed advanced ovarian cancer ［J］.N Engl J Med,2019,381(25):2391-2402.
[13]WEICHERT W,LUKASHCHUK N,YARUNIN A,et al.216 an evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer ［J］.International Journal of Gynecologic Cancer,2021,31(Suppl 3):A366.
[14]ZHANG J,SUN J,CHEN J,et al.Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer ［J］.Breast Cancer Research and Treatment,2016,158(3):455-462.
[15]SIKOV WM,BERRY DA,PEROU CM,et al.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer:CALGB 40603(Alliance) ［J］.J Clin Oncol,2015,33(1):13-21.
[16]MARQUARD AM,EKLUND AC,JOSHI T,et al.Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs ［J］.Biomark Res,2015,3:9.
[17]NEVIERE Z,DE LA MOTTE ROUGE T,FLOQUET A,et al.How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors ［J］.Ther Adv Med Oncol,2020,12:1758835919897530.

Memo

Memo:
National Natural Science Foundation of China（No.82174164）;国家自然科学基金资助项目(编号：82174164)
Last Update: 2023-01-31